Design and synthesis of dual-ligand modified chitosan as a liver targeting vector

Journal of Materials Science: Materials in Medicine

Volumn 23, Issue 2, 2012, Pages 431-441

  Chen, Houxiang ^a   Li, Min ^b   Wan, Tao ^a   Zheng, Qichang ^b   Cheng, Mingrong ^c   Huang, Shiqi ^a,c   Wang, Yong ^c  

^a WUHAN UNIVERSITY OF TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINES; CELL VIABILITY; CELLULAR UPTAKE; CONCENTRATION-DEPENDENT; FTIR; IN-VITRO; INHIBITORY CONCENTRATION; INVERSE PROPORTIONS; LACTOBIONIC ACID; LIVER TARGETING; MODIFIED CHITOSAN; MTT ASSAYS; NOVEL MATERIALS; ORTHOGONAL EXPERIMENT; TARGETED DRUG DELIVERY; TWO-STEP SYNTHESIS;

CELL CULTURE; CELLS; CHITOSAN; DRUG DELIVERY; LIGANDS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; VECTORS;

CHELATION;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHITOSAN; DUAL LIGAND MODIFIED CHITOSAN; GLYCYRRHETINIC ACID; LACTOBIONIC ACID; LIGAND; NANOPARTICLE; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; BINDING AFFINITY; CELL STRAIN; CELL VIABILITY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; DRUG UPTAKE; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HUMAN; HUMAN CELL; IC 50; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTITUTION REACTION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GALACTOSE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIGANDS; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, CHEMICAL; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84863467221     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-011-4494-1     Document Type: Article

References (31)

1. Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol. 2010;52:296-304.
2. Nguyen TH, Ferry N. Liver gene therapy: advances and hurdles. Gene Ther. 2004;11:S76-84.
3. Kinoshita H, Watanabe A, Hisayasu S, Suzuki S, Shimada T. Targeted gene delivery to selected liver segments via isolated hepatic perfusion. J Surg Res. 2010;160:47-51.
4. Sedlacek HH. Pharmacological aspects of targeting cancer gene therapy to endothelial cells. Crit Rev Oncol Hemat. 2001;37: 169-215.
5. Muzzarelli C, Muzzarelli RAA. Natural and artificial chitosan-inorganic composites. J Inorg Biochem. 2002;92:89-94.
6. Hamman JH. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar Drugs. 2010;8:1305-22.
7. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531-54.
8. Groman EV, Enriquez PM, Jung C, Josephson L. Arabinogalac-tan for hepatic drug delivery. Bioconj Chem. 1994;5:547-56.
9. Bom HS, Min JJ, Jeong HJ. Molecular nuclear imaging for tar-geting and trafficking. Nucl Eng Technol. 2006;38:399-404.
10. Schwartz AL, Rup D, Lodish HF. Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J Biol Chem. 1980;255:9033-6.
11. Baenziger JU, Fiete D. Galactose and 7V-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell. 1980;22:611-20.
12. Negishi M, Irie A, Nagata N, Ichikawa A. Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta. 1991;1066:77-82.
13. Ishida S, Sakiya Y, Ichikawa T, Taira Z. Uptake of glycyrrhizin by isolated rat hepatocytes. Biol Pharm Bull. 1993;16:293-7.
14. Obrian CA, Ward NE, Vogel VG. Inhibition of protein kinase C by the 12-0-tetradecanoylphorbol-13-acetate antagonist glyc-yrrhetic acid. Cancer Lett. 1990;49:9-12.
15. Yang L, Yang Z, Hu J, Huang S, Deng X, Miao X. Significance of the expression of glutamate decarboxylase 65 and protein kinase C in primary hepatocarcinoma tissues. Chin J Gen Surg. 2003;12:590-3.
16. Chung TW, Yang J, Akaike T, Cho KY, Nah JW, Kim SI, Cho CS. Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment. Biomaterials. 2002;23:2827-34.
17. Zheng YL, Wu Y, Yang WL, Wang CC, Fu SK, Shen XZ. Preparation, characterization, and drug release in vitro of chito-san-glycyrrhetic acid nanoparticles. J Pharm Sci. 2006;95: 181-91.
18. Feng ZQ, Chu XH, Huang NP, Wang T, Wang YC, Shi XL, Ding YT, Gu ZZ. The effect of nanofibrous galactosylated chitosan scaffolds on the formation of rat primary hepatocyte aggregates and the maintenance of liver function. Biomaterials. 2009;30: 2753-63.
19. Lu B, Wu DQ, Zheng H, Quan CY, Zhang XZ, Zhuo RX. Galac-tosyl conjugated Λ-succinyl-chitosan-graft-polyethylenimine for targeting gene transfer. Mol Bio Syst. 2010;6:2529-38.
20. Song BF, Zhang W, Peng R, Huang J, Me T, Li Y, Jiang Q, Gao R. Synthesis and cell activity of novel galactosylated chitosan as a gene carrier. Coll Surface B. 2009;70:181-6.
21. Tian Q, Wang XH, Wang W, Zhang CN, Liu YA, Yuan Z. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting. Int J Pharm. 2010;400:153-7.
22. Cheng MR, Li Q, Wan T, Hong XW, Chen HX, He B, Wu JB, Zhou RJ, et al. Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo. J Biomed Mater Res B Appl Biomater. 2011;99:70-80.
23. Stockert RJ, Morell AG. Hepatic binding protein: the galactose-specific receptor of mammalian hepatocytes. Hepatology. 1983; 3:750-7.
24. Tian Q, Zhang CN, Wang XH, Wang W, Huang W, Cha RT, Yuan Z, Tang H, et al. Glycyrrhetinic acid-modified chitosan/ poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials. 2010;31:4748-56.
25. Mi FL, Wu YY, Chiu YL, Chen MC, Suang HW, Yu SH, Shyu SS, Huang MF. Synthesis of a novel glycoconjugated chitosan and preparation of its derived nanoparticles for targeting Hep G2 cells. Biomacromolecules. 2007;8:892-8.
26. Sam S, Touahir L, Andresa JS, Allongue P, Chazalviel JN, Gouget-Laemmel AC, et al. Semiquantitative study of the EDC/ NHS activation of acid terminal groups at modified porous silicon surfaces. Langmuir. 2010;26:809-14.
27. Kalyan S, Sharma PK, Garg VK, Kumar JV, Varshney J. Recent advancement in chitosan based formulations and its pharmaceu-tical application. Der Pharmacia Sinica. 2010;1:195-210.
28. Chen G, Mi J, Wu XH, Luo CL, Li JB, Tang YX, Li J. Structural features and bioactivities of the chitosan. Int J Biol Macromol. 2011;49:543-7.
29. Lu B, Wang CF, Wu DQ, Li C, Zhang XZ, Zhuo RX. Chitosan based oligoamine polymers: synthesis, characterization, and gene delivery. J Control Release. 2009;137:54-62.
30. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100:5-28.
31. Wu L, Zhang J, Watanabe WW. Physical and chemical stability ofdrug nanoparticles. Adv Drug Deliv Rev. 2011;63:456-69.